Lanthio Pharma Raises €4.8 Million In Series A, Enters MorphoSys Pact
This article was originally published in The Pink Sheet Daily
Dutch biotech Lanthio Pharma has entered into an alliance with MorphoSys to develop its lantipeptide technology, with the German drug-discovery company also participating in Lanthio Pharma’s Series A funding round.
You may also be interested in...
Dutch start-up Dezima Pharma raises $18.6 million in Series A funding and government loans to move a next-generation CETP inhibitor to Phase III.
Plus recent news on BioTime, Lanthio, Applied Genetics Technology, and TauRx.
A $25 million upfront commitment could blossom into a deal worth as much as $1.1 billion plus royalties.